Amgen Inc. (NASDAQ:AMGN) Announces Dividend Increase – $2.52 Per Share

Amgen Inc. (NASDAQ:AMGN) declared a quarterly dividend on Tuesday, December 9th. Shareholders of record on Friday, February 13th will be paid a dividend of 2.52 per share by the medical research company on Friday, March 6th. This represents a c) annualized dividend and a yield of 3.2%. The ex-dividend date is Friday, February 13th. This is a 5.9% increase from Amgen’s previous quarterly dividend of $2.38.

Amgen has raised its dividend payment by an average of 0.1%per year over the last three years and has increased its dividend every year for the last 14 years. Amgen has a dividend payout ratio of 44.2% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Amgen to earn $21.39 per share next year, which means the company should continue to be able to cover its $9.52 annual dividend with an expected future payout ratio of 44.5%.

Amgen Stock Up 0.9%

Shares of Amgen stock traded up $2.76 during trading on Wednesday, hitting $316.61. 616,528 shares of the stock traded hands, compared to its average volume of 2,745,305. The stock has a market cap of $170.49 billion, a P/E ratio of 24.47, a PEG ratio of 2.90 and a beta of 0.45. The company has a fifty day moving average price of $314.99 and a two-hundred day moving average price of $298.07. Amgen has a twelve month low of $253.30 and a twelve month high of $346.38. The company has a debt-to-equity ratio of 5.45, a quick ratio of 0.99 and a current ratio of 1.28.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, topping analysts’ consensus estimates of $5.01 by $0.63. The firm had revenue of $9.56 billion for the quarter, compared to the consensus estimate of $8.98 billion. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The firm’s revenue was up 12.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $5.58 earnings per share. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Equities research analysts predict that Amgen will post 20.62 EPS for the current fiscal year.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.